AMD

Lessons from CANTREAT: fewer visits, BCVA improvement

Level 1 evidence now supports treat-and-extend vs. monthly intervals for anti-VEGF treatment of neovascular age-related macular degeneration.

Has the time come for AMD home monitoring?

An update on the progress of home-based OCT and how it could reduce treatment burden during and beyond the pandemic.

Long-term anti-VEGF effect: Six questions answered

A review of the evidence that suggests the beneficial effects of consistent treatment extend out to 10 years.

Potential of OCT to identify genetic risk in AMD

A look at our work in optical coherence tomography-derived drusen burden in non-advanced age-related macular degeneration.

More frequent dosing for refractory nAMD?

A closer look at biweekly anti-VEGF dosing for chronic disease that doesn’t respond completely to standard monthly dosing.

New revelations for nAMD, CSC treatments and ILM utility

Trial readouts on improving treatment durability, a potential new therapy for central serous chorioretinopathy and adding to the debate of RRD repair.

Gene therapy in AMD: Promises and challenges

Gene therapy could offer long-term stable control and prevent non-compliance, but the long-term effectiveness remains to be seen.

Gene therapy and editing for the retina: A primer

A look at advances in gene replacement therapy, gene delivery and CRISPR technology.

Is drier better in neovascular AMD?

It may depend on the location of the fluid. A quick look at HARBOR post-hoc results.

Pipeline Report: Despite major approvals, the queue gets longer

Treatments for exudative disease were notable for four significant exits from our listing and seven new entries this year.

Video Vault

Minimally invasive management of lenticular deposits

Akshay Thomas, MD, MS, of Tennessee Retina demonstrates his surgical technique for removing posterior intraocular lens deposits.